Pfizer (NYSE:PFE) admitted this morning that it has approached AstraZeneca (NASDAQ:AZN) twice seeking an opportunity to buy the company, most recently last weekend. In a conference call with analysts on Monday, Pfizer's management laid out the case for why AstraZeneca would be an excellent acquisition for Pfizer -- particularly given that Pfizer has reorganized into three business segments in preparation for a possible breakup in 2017.

In this video from Monday's Market Checkup, Motley Fool health care analysts Michael Douglass and David Williamson lay out the benefits of the acquisition point-by-point, laying out for investors the three reasons Pfizer wants AstraZeneca.